Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 4, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific transaction on August 31, 2006, where Abacus Corporate Trustees Limited, acting as trustee for the GlaxoSmithKline (US) Trust, sold 852 Ordinary Share ADRs at $56.80 per ADR on behalf of participants in the GlaxoSmithKline Share Value Plan. Additionally, the Trust transferred 1,644 Ordinary Share ADRs to plan participants.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the GSK Trust in the same capacity as other employees or former employees. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the impact of the 852 ADR sale and 1,644 ADR transfer on the total outstanding share count.
- Confirm the current status of the GlaxoSmithKline Share Value Plan and the GSK US Trust.
- Review the specific holdings of Directors Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop within the Trust.
- Check subsequent filings for any additional director transactions or changes in the Share Value Plan.